brivudine and Corneal-Ulcer

The results of a randomised double-blind clinical trial of 0.1% bromovinyldeoxyuridine (BVDU) and 1% trifluorothymidine (TFT) in 60 patients with corneal dendritic ulceration are presented. There was no significant difference between BVDU and TFT in terms of numbers of ulcers healed (p = 0.61), mean healing time (p = 0.065), and cumulative healing rate (p = 0.058). No serious side effects were observed, though transient stinging was recorded in five patients receiving TFT and in three patients receiving BVDU. One patient in the group treated with TFT developed a punctate epitheliopathy.

Topics: Adolescent; Adult; Aged; Antiviral Agents; Bromodeoxyuridine; Child; Corneal Ulcer; Double-Blind Method; Female; Humans; Keratitis, Dendritic; Male; Middle Aged; Time Factors; Trifluridine; Wound Healing

Fifty patients with corneal dendritic ulceration were randomly entered into a double blind clinical trial comparing BVDU eyedrops with TFT eyedrops. Of those receiving TFT 100% healed in a mean time of 6.7 days, while 92% of those receiving BVDU healed in a mean time of 8.7 days. There was no statistical difference between the two groups in terms of numbers healed, but BVDU was significantly slower in terms of days to heal. After a mean follow-up period of 7.5 months there has been one recurrence in each group.

Topics: Administration, Topical; Adolescent; Adult; Aged; Antiviral Agents; Bromodeoxyuridine; Child; Corneal Ulcer; Double-Blind Method; Female; Follow-Up Studies; Humans; Keratitis, Dendritic; Male; Middle Aged; Prognosis; Recurrence; Trifluridine

Patients suffering from dendritic and geographic corneal ulcers or herpetic stromal keratitis were treated with topical BVDU [(E)-5-(2-bromovinyl)-2'-deoxyuridine, bromovinyldeoxyuridine] 0.1% eyedrops administered during the day only at 1-hour intervals. Treatment with other antiviral drugs, i.e., idoxuridine, trifluridine, vidarabine or Zovirax had failed to ameliorate the ocular disease in 102 patients when their treatment was switched to BVDU eyedrops. Under BVDU therapy, dendritic keratitis in 44 patients healed within an average 7.8 days. Similarly, geographic corneal ulcers in 26 patients and stromal keratitis in 32 patients healed within an average period of 11.2 days and 30.7 days, respectively. Associated therapy with topical corticosteroids was stopped in 65 patients when the antiviral treatment was switched. However, topical corticosteroids had to be used together with BVDU drops to arrest stromal inflammation in 49 patients. Ultimately, 36 patients became corticosteroid-dependent. Except for local hypersensitivity reaction in three patients, BVDU eyedrops did not cause any toxic side effects.

Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antiviral Agents; Bromodeoxyuridine; Child; Child, Preschool; Corneal Ulcer; Drug Resistance, Microbial; Female; Follow-Up Studies; Humans; Infant; Keratitis, Dendritic; Male; Middle Aged; Ophthalmic Solutions; Prognosis; Recurrence; Simplexvirus

Topics: Animals; Antiviral Agents; Bromodeoxyuridine; Cornea; Corneal Ulcer; Epithelium; Eye Injuries; Idoxuridine; Ophthalmic Solutions; Rabbits; Wound Healing